Genset SA, Synthélabo deal

The companies will collaborate to discover and sequence genes associated with prostate cancer. The agreement is GENXY's first corporate partnership.

Synthélabo received an exclusive worldwide license to develop and sell small molecules, therapeutic proteins and therapeutic antibodies derived from genes discovered under the collaboration, to treat prostate cancer and potentially other prostatic diseases. ...